Skip to main content

Table 2 Comparison of SAR228810 with other clinical anti-amyloid antibodies in neuroprotection assay

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

% control response (no oAβ42)

oAβ42

5 μM

oAβ42 + SAR228810

oAβ42 + gantenerumab

oAβ42 + BAN-2401

50 μg/ml

150 μg/ml

50 μg/ml

150 μg/ml

50 μg/ml

150 μg/ml

Neurite network (MAP2)

49.84 ± 10.29

86.17 ± 10.25

96.49 ± 0.86

70.57 ± 1.66

82.27 ± 6.70

79.34 ± 0.70

86.78 ± 2.75

p < 0.0001

p < 0.0001

p = 0.0022

p < 0.0001

p = 0.0059

p < 0.0001

Caspase 3/7 activity

291.47 ± 48.73

190.84 ± 39.15

103.42 ± 10.36

388.89 ± 150.02

360.38 ± 123.53

428.48 ± 136.51

355.14 ± 124.57

p = 0.0001

p < 0.0001

NS

NS (p = 0.2562)

NS (p = 0.8675)

NS (p = 0.9995)

  1. Control response without oAβ42 = 100%; data are expressed as medians ± median absolute deviation (MAD); n = 3–7
  2. P values were obtained with a Dunnett‘s test versus oAβ42 after a one-way ANOVA on rank-transformed data
  3. NS not significant, oAβ oligomeric amyloid β